MedTrace Logo

Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica

NCT04644198 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-05-12

No results posted yet for this study

Summary

Corona virus Disease 2019 (COVID-19) can be a severe respiratory illness caused by Severe Acute Respiratory Syndrome (SARS-CoV2) for which there is no standard treatment in affected persons nor a vaccine to prevent the infection. The investigators propose to test whether the use of Convalescent plasma given to patients with severe COVID-19 disease will decrease risk of death, decrease use of ventilatory support decrease biomarkers of inflammation and improve measures of viral replication compared with controls subjects who were not transfused.Convalescent plasma, will be collected from persons who are more than 21 days post negative viral testing or 28 days post resolution of symptoms.

Conditions

  • COVID-19, Convalescent Plasma Treatment

Interventions

BIOLOGICAL

Convalescent Plasma Infusion

250 mls of convalescent plasma on day 1 \& 2.

Sponsors & Collaborators

  • The University of The West Indies

    lead OTHER

Principal Investigators

  • Gilian G Wharfe · University of the West Indies

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2021-12-01
Completion
2021-12-01

Countries

  • Jamaica

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04644198 on ClinicalTrials.gov